EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study

Emilio Berna-Rico, Esther Fiz-Benito, Jose Manuel Busto-Leis, Guillermo Servera-Negre, Raul de Lucas-Laguna, Marta Feito-Rodriguez

Dermatology · 2024

DOI: 10.1159/000535282 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Dermatology, 2024. Verfasst von Emilio Berna-Rico und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dupilumab has recently been shown to be effective in children under 6 years of age with atopic dermatitis (AD). Nevertheless, real-life and long-term follow-up data are scarce. We aimed to assess the effectiveness, safety, and long-term outcomes of dupilumab in a daily-practice setting in this age group.

Method

This was a retrospective observational cohort study. Only patients with 16 or more weeks of treatment were included in the analysis. The proportion of patients who achieved ≥75% or 90% reduction from baseline EASI (EASI75 and EASI90, respectively) and the percentage of patients who achieved vIGA 0–1 were analyzed at 4, 16, 48, 72, and 96 weeks (when available). Adverse events were recorded during follow-up.

Results

A total of 19 patients <6 years old with moderate-to-severe AD were included in the cohort, with a median age of 4.7 years (range: 2.6–5.9). The median weeks on dupilumab were 51.3 (IQR: 24.6–79.3). EASI75 was achieved in 11/19 patients (57.9%) at w4, 16/19 (84.2%) at w16, 9/12 (75%) at w48, 6/6 (100%) at w72, and in 2/2 (100%) at week 96. The objective of vIGA 0–1 was reached by 10/19 patients (51.6%) at w4, by 14/19 (73.7%) at w16, by 9/12 (75%) at w48, by 5/6 (83.3%) at w72, and by 2/2 (100%) at w96. Dupilumab was discontinued in 3 patients (15.8%) due to loss of response. One patient developed a paradoxical palmo-plantar eruption. We found no cases of conjunctivitis, facial erythema, or injection-site reactions related to dupilumab.

Conclusions

Dupilumab was effective and safe in our cohort of patients with moderate-to-severe AD under 6 years of age. Response was maintained in the long term in most patients with longer follow-up. Its adverse effect profile was similar to that found in older children and adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDermatitis, AtopicChild, PreschoolHumansCohort StudiesDouble-Blind MethodRetrospective StudiesSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

Atopic dermatitisDupilumabEczemaTherapeutics

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain.

Zitieren

APA

Berna-Rico, E., Fiz-Benito, E., Busto-Leis, J. M., Servera-Negre, G., de Lucas-Laguna, R., & Feito-Rodriguez, M. (2024). Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study. Dermatology. https://doi.org/10.1159/000535282

Vancouver

Berna-Rico E, Fiz-Benito E, Busto-Leis JM, Servera-Negre G, de Lucas-Laguna R, Feito-Rodriguez M. Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study. Dermatology. 2024. doi:10.1159/000535282

BibTeX
@article{BernaRico2024,
  author = {Berna-Rico, Emilio and Fiz-Benito, Esther and Busto-Leis, Jose Manuel and Servera-Negre, Guillermo and de Lucas-Laguna, Raul and Feito-Rodriguez, Marta},
  title = {Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study},
  journal = {Dermatology},
  year = {2024},
  doi = {10.1159/000535282}
}
Kostenlos starten →